The present invention provides a composition for restoration of tissue including a biodegradable polymeric copolymer which is obtained by polymerizing a hydrophobic biodegradable polymer and a hydrophilic biodegradable polymer. The composition of the present invention has excellent tissue restoration effects because of high collagen production rate without occurrence of nodules even when injected directly into the dermis, unlike the conventional composition for restoration of tissue.

Provided herein are methods of making degradable, additive-blended polymeric materials using microwave radiation and catalysts. The methods can include incorporation of therapeutic materials into the polymeric materials. There also are provided polymeric materials made by the methods and medical devices comprising the polymeric materials made by the methods.

Provided is a method for manufacturing an LCP film for a circuit substrate capable of achieving an LCP film for a circuit substrate having a low coefficient of linear thermal expansion and excellent dimensional stability, without excessively impairing excellent basic performance possessed by the liquid crystal polyester, such as mechanical characteristics, electrical characteristics, and heat resistance. The method for manufacturing an LCP film for a circuit substrate at least comprising: a composition provision step of providing an LCP resin composition at least containing 100 parts by mass of a liquid crystal polyester and 1 to 20 parts by mass of a polyarylate; a film forming step of T-die melt-extruding the LCP resin composition to form a T-die melt-extruded LCP film having a coefficient of linear thermal expansion (α2) in a TD direction of 50 ppm/K or more; and a pressurizing and heating step of subjecting the T-die melt-extruded LCP film to pressure and heat treatment to obtain an LCP film for a circuit substrate having a coefficient of linear thermal expansion (α2) in the TD direction of 16.8±12 ppm/K.

Provided is a method for manufacturing an LCP film for a circuit substrate capable of achieving an LCP film for a circuit substrate having a low coefficient of linear thermal expansion and excellent dimensional stability, without excessively impairing excellent basic performance possessed by the liquid crystal polyester, such as mechanical characteristics, electrical characteristics, and heat resistance. The method for manufacturing an LCP film for a circuit substrate at least comprising: a composition provision step of providing an LCP resin composition at least containing 100 parts by mass of a liquid crystal polyester and 1 to 20 parts by mass of a polyarylate; a film forming step of T-die melt-extruding the LCP resin composition to form a T-die melt-extruded LCP film having a coefficient of linear thermal expansion (α2) in a TD direction of 50 ppm/K or more; and a pressurizing and heating step of subjecting the T-die melt-extruded LCP film to pressure and heat treatment to obtain an LCP film for a circuit substrate having a coefficient of linear thermal expansion (α2) in the TD direction of 16.8±12 ppm/K.

The present disclosure provides copolymers useful in medical devices. For example, the disclosure provides copolymers comprising the polymerization product ester block, ether blocks and diisocyanates. In certain embodiments, the disclosure provides a medical copolymer for implantation comprising ester blocks and ether blocks, wherein: the ester blocks comprise a negative free energy transfer and the ether blocks comprise a positive free energy transfer, the ether and ester blocks are less than 1/10 the length of said copolymer, and, the blocks are distributed such that no domain of contiguous blocks possessing the same polarity of free energy transfer are less than ⅓ of the molecular weight of the copolymer. The disclosure further provides methods of making the aforementioned polymers, and medical devices comprising the polymers.

The present disclosure provides copolymers useful in medical devices. For example, the disclosure provides copolymers comprising the polymerization product ester block, ether blocks and diisocyanates. In certain embodiments, the disclosure provides a medical copolymer for implantation comprising ester blocks and ether blocks, wherein: the ester blocks comprise a negative free energy transfer and the ether blocks comprise a positive free energy transfer, the ether and ester blocks are less than 1/10 the length of said copolymer, and, the blocks are distributed such that no domain of contiguous blocks possessing the same polarity of free energy transfer are less than ⅓ of the molecular weight of the copolymer. The disclosure further provides methods of making the aforementioned polymers, and medical devices comprising the polymers.

A tissue restoration composition in a colloidal phase, includes a copolymer in which a hydrophobic biocompatible polymer and a hydrophilic biocompatible polymer are polymerized and which is dispersed in water. The colloidal phase has increased viscosity by heating the copolymer dispersed in water. The colloidal phase has a viscosity, by the heating, of 20-200,000 cP.

A tissue restoration composition in a colloidal phase, includes a copolymer in which a hydrophobic biocompatible polymer and a hydrophilic biocompatible polymer are polymerized and which is dispersed in water. The colloidal phase has increased viscosity by heating the copolymer dispersed in water. The colloidal phase has a viscosity, by the heating, of 20-200,000 cP.

The invention provides methods for the formation of thermo-reversible hydrogels from triblock copolymers of poly(ethylene glycol) and poly(α-benzyl carboxylate-ε-caprolactone) (PBCL-PEG-PBCL) prepared by bulk and solution polymerization. PBCL-PEG-PBCLs prepared at fixed PBCL to PEG ratios but different polymerization times were characterized for their average molecular weights, molar-mass disparity and intrinsic viscosity using .sup.1H NMR and gel permeation chromatography (GPC). The results indicated a copolymer of high molecular weight population with elevated intrinsic viscosity. The size and proportion of this population grew as a function of polymerization time. The formation of this high molecular weight PBCL-PEG-PBCL population can be attributed to non-linear architecture caused by partial cross-linking of the PBCL segment during the polymerization reaction. At least about 40% mole concentration of the high molecular weight PBCL-PEG-PBCL was required for thermo-reversible micellar aggregation in aqueous media and hydrogel formation.

Liquid polymer pharmaceutical compositions with a biodegradable liquid polymer, a biocompatible solvent or combination or mixture of solvents and/or co-solvents, and an active pharmaceutical agent comprising a peptide are useful to provide extended long-term release of the drug to a subject and/or to improve the stability of the active pharmaceutical agent. In embodiments, the polymer may be initiated with a low-molecular weight polyethylene glycol and/or may be a block copolymer comprising a low-molecular weight polyethylene glycol block. In further embodiments, the liquid polymer pharmaceutical composition may include a divalent cation, which may be provided in the form of a metal salt.